Free Trial
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

ACADIA Pharmaceuticals logo
$17.23 +0.44 (+2.62%)
Closing price 04:00 PM Eastern
Extended Trading
$17.23 0.00 (0.00%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

Key Stats

Today's Range
$17.02
$17.50
50-Day Range
$16.77
$20.37
52-Week Range
$14.15
$20.68
Volume
1.07 million shs
Average Volume
1.77 million shs
Market Capitalization
$2.87 billion
P/E Ratio
22.09
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Moderate Buy

Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Remove Ads

ACADIA Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

ACAD MarketRank™: 

ACADIA Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 94th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 9 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ACADIA Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ACADIA Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ACADIA Pharmaceuticals is 22.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ACADIA Pharmaceuticals is 22.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.70.

  • Price to Book Value per Share Ratio

    ACADIA Pharmaceuticals has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ACADIA Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.07% of the float of ACADIA Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in ACADIA Pharmaceuticals has recently decreased by 5.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ACADIA Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ACADIA Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.07% of the float of ACADIA Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in ACADIA Pharmaceuticals has recently decreased by 5.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ACADIA Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    Only 6 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $114,583.00 in company stock.

  • Percentage Held by Insiders

    28.30% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ACADIA Pharmaceuticals' insider trading history.
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Zacks Research Brokers Reduce Earnings Estimates for ACAD
Stoke Therapeutics reports Q EPS (18c), consensus (53c)
See More Headlines

ACAD Stock Analysis - Frequently Asked Questions

ACADIA Pharmaceuticals' stock was trading at $18.35 on January 1st, 2025. Since then, ACAD stock has decreased by 6.1% and is now trading at $17.23.
View the best growth stocks for 2025 here
.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals's quarterly revenue was up 18.3% on a year-over-year basis.

Top institutional investors of ACADIA Pharmaceuticals include Vanguard Group Inc. (8.38%), RTW Investments LP (5.23%), D. E. Shaw & Co. Inc. (1.95%) and Geode Capital Management LLC (1.73%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Brendan Teehan, Srdjan R Stankovic, Mark C Schneyer, Austin D Kim, James Kihara, Elizabeth A Garofalo and Laura Brege.
View institutional ownership trends
.

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
11/06/2024
Today
3/24/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACAD
Employees
510
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$31.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+39.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
17 Analysts

Profitability

Trailing P/E Ratio
22.09
Forward P/E Ratio
24.61
P/E Growth
N/A
Net Income
$-61,290,000.00
Pretax Margin
14.71%

Debt

Sales & Book Value

Annual Sales
$957.80 million
Price / Cash Flow
N/A
Book Value
$2.63 per share
Price / Book
6.55

Miscellaneous

Free Float
119,303,000
Market Cap
$2.87 billion
Optionable
Optionable
Beta
0.43

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ACAD) was last updated on 3/24/2025 by MarketBeat.com Staff
From Our Partners